Mirabella Financial Services LLP Trims Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mirabella Financial Services LLP reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 87.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,817 shares of the company's stock after selling 20,539 shares during the quarter. Mirabella Financial Services LLP's holdings in IDEXX Laboratories were worth $1,164,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. MetLife Investment Management LLC increased its position in IDEXX Laboratories by 0.3% during the 4th quarter. MetLife Investment Management LLC now owns 25,245 shares of the company's stock valued at $10,437,000 after purchasing an additional 85 shares during the period. Norinchukin Bank The increased its position in shares of IDEXX Laboratories by 9.0% during the fourth quarter. Norinchukin Bank The now owns 5,594 shares of the company's stock valued at $2,313,000 after buying an additional 460 shares during the period. Ossiam raised its stake in IDEXX Laboratories by 28.2% in the fourth quarter. Ossiam now owns 5,028 shares of the company's stock worth $2,079,000 after buying an additional 1,105 shares in the last quarter. Beck Mack & Oliver LLC lifted its holdings in IDEXX Laboratories by 3.8% in the fourth quarter. Beck Mack & Oliver LLC now owns 2,092 shares of the company's stock worth $865,000 after buying an additional 77 shares during the period. Finally, Capital Research Global Investors boosted its position in IDEXX Laboratories by 44.4% during the 4th quarter. Capital Research Global Investors now owns 615,996 shares of the company's stock valued at $254,677,000 after acquiring an additional 189,436 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research note on Monday, April 14th. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $523.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 0.8 %

IDXX traded down $3.54 on Friday, reaching $437.44. 939,257 shares of the company traded hands, compared to its average volume of 631,554. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company has a market cap of $35.45 billion, a P/E ratio of 41.00, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The firm has a fifty day simple moving average of $420.16 and a two-hundred day simple moving average of $429.68. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.